Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVEC.L Share News (VEC)

  • There is currently no data for VEC

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Numis adds Virgin Money, Derwent and Northgate to 'top picks' list

Fri, 01st Apr 2016 15:34

(ShareCast News) - Numis sell-side analysts provided a list of their top picks among large and small cap stocks across the market, including ARM Holdings, Virgin Money, Derwent London, Tullow Oil, Northgate and Vectura.After another strong set of quarterly results, ARM remains the top pick as Numis believes the recent investments should be taken as a sign of confidence that historic growth rates can be sustained as ARM deepens its value add in existing markets and continues to address new markets."The analyst meeting indicated confidence in further growth in mobile despite slower growth in smartphone volumes, with growth coming from higher royalties with increased performance as with v8, multiple cores and additional IP," the broker said, with strong prospects in enterprise infrastructure and 'embedded intelligence'.The stock trades at a p/e of 28.8x, below the bottom of the 30-55x historic range, whereas prospects to sustain earnings growth at least in the high teens "continue to remain very strong".Virgin Money was added to the list on the view that it will continue to benefit from both strong earnings growth and improving return on tangible equity (ROTE) while markets remain favourable and mainstream competition is "distracted/restricted"."Furthermore, improved utilisation of the operating infrastructure acquired from Northern Rock should, in our view, underpin significant balance sheet growth for very little incremental cost." A target price of 490p is more than £1 above the current market price.Derwent London is another new addition to the top picks portfolio, replacing British Land, with the comment that its return profile evolved through FY15 with the mix of returns has shifting from yields to estimated rental value (ERV) growth.ERVs have been accelerating since early 2013, they remain some way below levels seen in 2006 but, while slowing, are thought likely to remain positive through to 2019."Rising construction capacity constraints and cost inflation increase the likelihood of delays across the broader London development pipeline but DLN has locked in construction packages and costs, in sterling-terms, on three of its four live developments, and is close to finalising the remaining package for 80 Charlotte St."While there are macro uncertainties such as the mayoral election and Brexit vote, a strong balance sheet, an attractive development pipeline and significant organic reversion off low passing rents, gives analysts confidence in their 3,850p target price.Tullow, despite being among the most shorted stocks on the FTSE, remains in the list on analysts belief that Tullow "could be ideally positioned for a future recovery in oil prices", as it is able to withstand a period of low oil prices while completing its major development project, the TEN field offshore Ghana where first oil is due in the middle of this year.On Vectura, Numis set a price target of 264p, offering around 60% updside to the current price on a 12-month view as the respiratory specialist merges with peer Skyepharma in "one of the most complementary mergers in the UK Healthcare sector", as the enlarged group has competitive advantages in both drug delivery and respiratory formulations and offers exposure to several emerging royalty streams through partnerships with Big Pharma partners."Vectura specifically benefits from Skyepharma's fast growing earnings and cash-flow, which will, in our opinion, accelerate the enlarged group's transition to being a specialist pharmaceutical company with the financial strength to commercialise novel drugs and devices in niche segments itself."House stock Northgate is another new name on the list, with a target price of 560p as the shares are felt to offer an "attractive combination of cyclical and selfhelp growth drivers, income attractions, and a valuation that reflects the historicchanges to the depreciation rates and UK operational issues, rather than the scope for further improvement".
More News
19 Mar 2021 09:46

BROKER RATINGS: Barclays and Goldman Sachs downgrade Hammerson

BROKER RATINGS: Barclays and Goldman Sachs downgrade Hammerson

Read more
18 Mar 2021 10:36

Vectura shares rise on swing to profit, GBP115 million special payout

Vectura shares rise on swing to profit, GBP115 million special payout

Read more
18 Mar 2021 07:43

Royalty income, litigation win see Vectura beat expectations

(Sharecast News) - Vectura reported a 6.9% improvement in its total revenue on Thursday, to £190.6m, driven by development services and a surge in income from royalties.

Read more
11 Mar 2021 16:13

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
5 Mar 2021 12:29

Vectura delays results because of KPMG staff shortage

(Sharecast News) - Vectura delayed the publication of its annual results after KPMG asked for more time to audit the accounts because of a staff shortage caused by Covid-19.

Read more
2 Mar 2021 16:01

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
22 Jan 2021 09:32

LONDON BROKER RATINGS SUMMARY: Deutsche Bank Ups British Land, Landsec

LONDON BROKER RATINGS SUMMARY: Deutsche Bank Ups British Land, Landsec

Read more
12 Jan 2021 10:13

Vectura Forecasts 2020 Earnings To Top Board Expectations

Vectura Forecasts 2020 Earnings To Top Board Expectations

Read more
12 Jan 2021 08:16

Vectura reports 'strong' operational performance in 2020

(Sharecast News) - Inhaled medicines-focussed pharmaceutical company Vectura Group updated the market on its trading on Tuesday, saying it expected revenue and adjusted EBITDA for 2020 to be ahead of board expectations, following the fourth quarter approval of VR315 (US), or generic 'Advair', alongside Hikma.

Read more
30 Dec 2020 19:10

UK EXECUTIVE CHANGE SUMMARY: Nutrition Firm Director Joins Tate & Lyle

UK EXECUTIVE CHANGE SUMMARY: Nutrition Firm Director Joins Tate & Lyle

Read more
29 Dec 2020 12:04

Vectura Says Glaxo Will Not Appeal Award In Ellipta Litigation

Vectura Says Glaxo Will Not Appeal Award In Ellipta Litigation

Read more
29 Dec 2020 10:04

Glaxo not seeking re-hearing in Ellipta litigation, says Vectura

(Sharecast News) - Vectura said on Tuesday that GlaxoSmithKline has not sought to petition the US Court of Appeals for a re-hearing in the companies' ongoing litigation over GSK's Ellipta inhalers.

Read more
18 Dec 2020 17:08

LONDON MARKET CLOSE: Stocks Fall As Investors Sweat On Brexit Deal

LONDON MARKET CLOSE: Stocks Fall As Investors Sweat On Brexit Deal

Read more
18 Dec 2020 12:08

LONDON MARKET MIDDAY: FTSE 100 Rises As Crunch Brexit Talks Dent Pound

LONDON MARKET MIDDAY: FTSE 100 Rises As Crunch Brexit Talks Dent Pound

Read more
18 Dec 2020 10:45

UK WINNERS & LOSERS SUMMARY: US Generic Advair Ok Lifts Hikma, Vectura

UK WINNERS & LOSERS SUMMARY: US Generic Advair Ok Lifts Hikma, Vectura

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.